

**DISCLOSURE OF MOVEMENT OF 1% OR MORE IN SUBSTANTIAL HOLDING OR
CHANGE IN NATURE OF RELEVANT INTEREST, OR BOTH**

Sections 277 and 278, Financial Markets Conduct Act 2013

TO: NZX Limited

and

TO: Finzsoft Solutions Limited ("**FIN**")

Relevant event being disclosed: Movement of 1% or more in substantial holding

Date of relevant event: 20 March 2015

Date this disclosure made: 20 March 2015

Date last disclosure made: 17 March 2015

Substantial product holder giving disclosure

Full name(s): HGH (ICT Investments No. 2) Limited ("**HGH2**")

Summary of previous substantial holding

Class of quoted voting products: Ordinary shares

Summary for: HGH 2

For **this** disclosure:

(a) total number held in class: 6,608,719

(b) total in class: 8,566,164

(c) total percentage held in class: 77.149%

For **last** disclosure:

(a) total number held in class: 6,452,469

(b) total in class: 8,566,164

(c) total percentage held in class: 75.325%

Details of transactions and events giving rise to relevant event

Details of the transactions or other events requiring disclosure:

On 27 February 2015, Silverlake HGH Limited (“**Silverlake HGH**”) made a full takeover offer under the Takeovers Code to acquire all the equity securities in FIN (“**Offer**”).

Since the last disclosure dated 17 March 2015, Silverlake HGH has become the legal and beneficial owner of a further 156,250 ordinary shares in FIN. As at the time of this notice, Silverlake HGH is the registered holder and beneficial owner of 6,608,719 ordinary shares in FIN, in aggregate (representing 77.149% of all of the ordinary shares in FIN).

Clause 31.12 of Silverlake HGH’s constitution contains deadlock provisions which provide that after 18 December 2019, if the board of Silverlake HGH cannot agree on a “Fundamental Matter” (as defined in the constitution), either Silverlake Axis Ltd or HGH2 may give notice to the other specifying a cash price at which Silverlake HGH will sell all of the financial products in FIN beneficially owned by Silverlake HGH to Silverlake Axis Ltd or HGH2. Silverlake Axis Ltd and HGH2 must take all steps to give effect to that transaction, including, to the extent required by law, by making a full takeover offer for FIN under the Takeovers Code in order to facilitate the sale and purchase of Silverlake HGH’s financial products in FIN.

Details after relevant event

Details for:

HGH2

Nature of relevant interest(s):

Future power to control the disposition of all of the financial products in FIN beneficially owned by Silverlake HGH pursuant to clause 31.12 of Silverlake HGH’s constitution.

For that relevant interest:

- | | | |
|-----|-----------------------------------------------------|----------------|
| (a) | number held in class: | 6,608,719 |
| (b) | percentage held in class: | 77.149% |
| (c) | current registered holder(s): | Silverlake HGH |
| (d) | registered holder(s) once transfers are registered: | NA |

Additional information

Address(es) of substantial product holder(s): 22 Winscombe Street, Belmont, Auckland, 0622

Contact details: Andrew Holliday
Phone: +64 21 355 492
Email: Andrew.Holliday@finzsoft.com

Name of any other person believed to have given, or believed to be required to give, a disclosure under the Financial Markets Conduct Act 2013 in relation to the financial products to which this disclosure relates: Silverlake HGH and Silverlake Axis Ltd.

Certification

I, Andrew Alexander Holliday, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.